MAPT and dementia: Despite the fact that neurofibrillary tau pathology correlates much more closely with clinical symptoms of dementia than amyloid pathology, drug discovery and development efforts for AD in the last two decades have primarily focused on targets related to β-amyloid, so far with highly disappointing results.